EP3504187A4 - Use of pridopidine for treating functional decline - Google Patents
Use of pridopidine for treating functional decline Download PDFInfo
- Publication number
- EP3504187A4 EP3504187A4 EP17844433.7A EP17844433A EP3504187A4 EP 3504187 A4 EP3504187 A4 EP 3504187A4 EP 17844433 A EP17844433 A EP 17844433A EP 3504187 A4 EP3504187 A4 EP 3504187A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pridopidine
- functional decline
- treating functional
- treating
- decline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008717 functional decline Effects 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662379175P | 2016-08-24 | 2016-08-24 | |
US201662395263P | 2016-09-15 | 2016-09-15 | |
US201662411511P | 2016-10-21 | 2016-10-21 | |
US201662416685P | 2016-11-02 | 2016-11-02 | |
PCT/US2017/048461 WO2018039477A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating functional decline |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3504187A1 EP3504187A1 (en) | 2019-07-03 |
EP3504187A4 true EP3504187A4 (en) | 2020-05-06 |
Family
ID=61241181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17844433.7A Pending EP3504187A4 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating functional decline |
Country Status (11)
Country | Link |
---|---|
US (1) | US11207310B2 (en) |
EP (1) | EP3504187A4 (en) |
JP (2) | JP6912574B2 (en) |
CN (2) | CN109923102B (en) |
AU (2) | AU2017315783C1 (en) |
BR (1) | BR112019003732A2 (en) |
CA (2) | CA3151507A1 (en) |
CL (2) | CL2019000485A1 (en) |
IL (1) | IL311081A (en) |
MX (2) | MX2019002265A (en) |
WO (1) | WO2018039477A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
MX2015017307A (en) | 2013-06-21 | 2016-08-03 | Teva Pharmaceuticals Int Gmbh | Use of high dose pridopidine for treating huntington's disease. |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
JP6887952B2 (en) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | Use of pridopidin to improve cognitive function and to treat Alzheimer's disease |
JP7278210B2 (en) * | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | Use of Pridopidine to Treat Dystonia |
JP6912574B2 (en) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | Use of predopidine to treat hypofunction |
PE20190979A1 (en) | 2016-09-15 | 2019-07-09 | Boehringer Ingelheim Int | HETEROARILCARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 |
JP2020533296A (en) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | Pridopidine for the treatment of drug-induced dyskinesia |
BR112021024744A2 (en) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Method to improve, maintain or reduce impairment of functional capacity and motor function in a human patient with Huntington's disease |
AU2021266476A1 (en) * | 2020-05-04 | 2022-11-24 | Prilenia Neurotherapeutics Ltd. | Treatment of viral infection, disease or disorder using a selective S1R agonist |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013086425A1 (en) * | 2011-12-08 | 2013-06-13 | IVAX International GmbH | The hydrobromide salt of pridopidine |
WO2016138130A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9702716D0 (en) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
SE9904724D0 (en) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
WO2005053703A1 (en) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
GT200500063A (en) | 2004-04-01 | 2005-10-14 | METHOD FOR TREATMENT OF SCHIZOPHRENIA AND / OR GLUCOREGULATORY ABNORMALITIES | |
CN101056854B (en) | 2004-10-13 | 2013-06-05 | Nsab神经研究瑞典公司分公司 | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine |
PE20071092A1 (en) | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | PHARMACEUTICAL COMPOSITION INCLUDING A CB1 ANTAGONIST AND AN ANTI-SYMPTOM AGENT |
EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
US20070286902A1 (en) | 2006-06-07 | 2007-12-13 | Abrika Pharmaceuticals | Dosage forms comprising a short acting sedative-hypnotic or salt thereof |
AU2008239841B2 (en) | 2007-04-12 | 2013-07-18 | Teva Pharmaceuticals International Gmbh | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
ES2804779T3 (en) | 2009-09-24 | 2021-02-09 | Capsugel Belgium Nv | Acid resistant capsules |
US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
CN103080343A (en) | 2010-07-02 | 2013-05-01 | Skf公司 | Mechanical component and method for surface hardening |
US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
EP2710041A4 (en) | 2011-05-18 | 2014-11-05 | Parkinson S Inst | Assay to determine lrrk2 activity in parkinson's disease |
JP6189299B2 (en) | 2011-09-07 | 2017-08-30 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | A novel polymorphic form of pridopidine hydrochloride |
US9744155B2 (en) * | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
CN104470585A (en) | 2012-04-04 | 2015-03-25 | 爱华克斯国际有限公司 | Pharmaceutical compositions for combination therapy |
US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
AU2013323133A1 (en) | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
MX2015017307A (en) | 2013-06-21 | 2016-08-03 | Teva Pharmaceuticals Int Gmbh | Use of high dose pridopidine for treating huntington's disease. |
EP3096759B1 (en) | 2014-01-22 | 2022-04-06 | Prilenia Neurotherapeutics Ltd. | Modified release formulations of pridopidine |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
AR105434A1 (en) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | PROCESS TO PREPARE PRIDOPIDINE |
WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
JP6912574B2 (en) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | Use of predopidine to treat hypofunction |
JP7278210B2 (en) | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | Use of Pridopidine to Treat Dystonia |
CA3036842A1 (en) | 2016-09-15 | 2018-03-22 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for the treatment of anxiety and depression |
CN109982686A (en) | 2016-09-16 | 2019-07-05 | 普瑞尼亚医疗发展有限公司 | More purposes determined for treating RETT syndrome of Puli |
WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
BR112019015000A2 (en) | 2017-01-20 | 2020-04-07 | Agency Science Tech & Res | use of pridopidine for the treatment of fragile x syndrome |
JP7082186B2 (en) | 2017-08-14 | 2022-06-07 | プリレニア ニューロセラピューティクス リミテッド | How to treat amyotrophic lateral sclerosis with pridopidin |
CN111278431A (en) | 2017-08-30 | 2020-06-12 | 普瑞尼亚神经治疗有限公司 | High concentration dosage forms of pridopidine |
-
2017
- 2017-08-24 JP JP2019531547A patent/JP6912574B2/en active Active
- 2017-08-24 CA CA3151507A patent/CA3151507A1/en active Pending
- 2017-08-24 WO PCT/US2017/048461 patent/WO2018039477A1/en unknown
- 2017-08-24 MX MX2019002265A patent/MX2019002265A/en unknown
- 2017-08-24 CA CA3035092A patent/CA3035092C/en active Active
- 2017-08-24 IL IL311081A patent/IL311081A/en unknown
- 2017-08-24 BR BR112019003732-2A patent/BR112019003732A2/en active Search and Examination
- 2017-08-24 CN CN201780066778.4A patent/CN109923102B/en active Active
- 2017-08-24 EP EP17844433.7A patent/EP3504187A4/en active Pending
- 2017-08-24 CN CN202211419342.8A patent/CN115671103A/en active Pending
- 2017-08-24 US US15/685,993 patent/US11207310B2/en active Active
- 2017-08-24 AU AU2017315783A patent/AU2017315783C1/en active Active
-
2019
- 2019-02-22 CL CL2019000485A patent/CL2019000485A1/en unknown
- 2019-02-25 MX MX2022003072A patent/MX2022003072A/en unknown
- 2019-12-31 CL CL2019003924A patent/CL2019003924A1/en unknown
-
2020
- 2020-08-27 AU AU2020223736A patent/AU2020223736B2/en active Active
-
2021
- 2021-05-06 JP JP2021078504A patent/JP2021119186A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013086425A1 (en) * | 2011-12-08 | 2013-06-13 | IVAX International GmbH | The hydrobromide salt of pridopidine |
WO2016138130A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
Non-Patent Citations (3)
Title |
---|
ANON: "Unified Huntington's Disease Rating Scale: Reliability and-Consis tenc y", MOVEMENT DISORDERS, vol. 11, no. 2, 1 January 1996 (1996-01-01), pages 136 - 142, XP055677965 * |
FERDINANDO SQUITIERI ET AL: "Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date", DRUG DESIGN, DEVELOPMENT AND THERAPY, 28 October 2015 (2015-10-28), United Kingdom, pages 5827, XP055485261, ISSN: 1177-8881, DOI: 10.2147/DDDT.S65738 * |
ZIELONKA DANIEL ET AL: "Update on Huntington's disease: Advances in care and emerging therapeutic options", PARKINSONISM AND RELATED DISORDERS, vol. 21, no. 3, 19 December 2014 (2014-12-19), pages 169 - 178, XP029200000, ISSN: 1353-8020, DOI: 10.1016/J.PARKRELDIS.2014.12.013 * |
Also Published As
Publication number | Publication date |
---|---|
US11207310B2 (en) | 2021-12-28 |
AU2017315783C1 (en) | 2020-12-24 |
CN115671103A (en) | 2023-02-03 |
EP3504187A1 (en) | 2019-07-03 |
CL2019000485A1 (en) | 2019-07-12 |
AU2020223736B2 (en) | 2022-04-07 |
CN109923102B (en) | 2022-11-15 |
CA3035092C (en) | 2022-05-31 |
US20180055832A1 (en) | 2018-03-01 |
WO2018039477A1 (en) | 2018-03-01 |
IL311081A (en) | 2024-04-01 |
MX2019002265A (en) | 2019-10-30 |
AU2020223736A1 (en) | 2020-09-17 |
JP6912574B2 (en) | 2021-08-04 |
CA3035092A1 (en) | 2018-03-01 |
BR112019003732A2 (en) | 2020-02-18 |
CN109923102A (en) | 2019-06-21 |
CA3151507A1 (en) | 2018-03-01 |
JP2021119186A (en) | 2021-08-12 |
AU2017315783A1 (en) | 2019-04-11 |
MX2022003072A (en) | 2022-06-17 |
JP2019524898A (en) | 2019-09-05 |
AU2017315783B2 (en) | 2020-05-28 |
CL2019003924A1 (en) | 2020-05-29 |
NZ751156A (en) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3548071A4 (en) | Methods for treatment of cancer comprising tigit-binding agents | |
EP3504187A4 (en) | Use of pridopidine for treating functional decline | |
EP3426250A4 (en) | Methods of treatment | |
EP3256218A4 (en) | Kdm1a inhibitors for the treatment of disease | |
EP3252124A4 (en) | Surface treatment agent | |
EP3409744A4 (en) | Surface treatment agent | |
EP3373969A4 (en) | Glycan-interacting compounds and methods of use | |
EP3134436A4 (en) | Treatment of h-ras-driven tumors | |
EP3157565A4 (en) | Treatment of polybacterials infections | |
EP3564335A4 (en) | Surface treatment agent | |
EP3389645A4 (en) | Combinations for the treatment of cancer | |
EP3179993A4 (en) | Method for the treatment of depression | |
EP3503890A4 (en) | Use of pridopidine for treating dystonias | |
EP3139919A4 (en) | Compounds for treatment of cancer | |
EP3548028A4 (en) | Treatment of cancer | |
EP3490561A4 (en) | Combinations for the treatment of cancer | |
EP3431566A4 (en) | Surface treatment agent | |
EP3503887A4 (en) | Combinations for the treatment of cancer | |
EP3122349A4 (en) | Compositions for the treatment of autodigestion | |
EP3119390A4 (en) | Methods of treating cancer | |
EP3215148A4 (en) | Methods for treatment of cognitive decline | |
EP3472623A4 (en) | Exosome-guided treatment of cancer | |
EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
EP3309165A4 (en) | Surface treatment agent | |
EP3491129A4 (en) | Methods of treating osmidrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190322 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PRILENIA NEUROTHERAPEUTICS LTD. |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200402 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 211/42 20060101AFI20200328BHEP Ipc: A61K 31/451 20060101ALI20200328BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40009736 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220919 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |